Mitochondrial DNA-related mitochondrial dysfunction in neurodegenerative diseases

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 3, 2002, Pages 271-280

  Swerdlow, Russell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

APOPTOSIS; ARTICLE; CELL ORGANELLE; CYBRID; DEGENERATIVE DISEASE; GENOTYPE PHENOTYPE CORRELATION; PATHOGENESIS; PATHOPHYSIOLOGY;

APOPTOSIS; CELL FUSION; DNA, MITOCHONDRIAL; HUMANS; HYBRID CELLS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES;

EID: 0036189213     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Sporadic neurologic disease and the electron transport chain: A hypothesis
2. Keilin's respiratory chain concept and its chemiosmotic consequences
3. Sequence and organization of the human mitochondrial genome
4. Mitochondrial DNA: Advances, problems, and goals
5. Mitochondrial DNA in mortal and immortal human cells
6. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins
7. Diseases of the mitochondrial DNA
8. Molecularly confirmed Leber's hereditary optic neuropathy
9. Leber's hereditary optic neuropathy
10. Protein import into mitochondria
11. Aging, energy, and oxidative stress in neurodegenerative diseases
12. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
13. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
14. Implication of mitochondria in apoptosis
15. The development of mitochondrial medicine
16. The biochemical basis of mitochondrial diseases
17. Mitochondrial DNA Mutation associated with Leber hereditary optic neuropathy
18. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies
19. Deletions of mitochondrial DNA in Kearns-Sayre syndrome
20. Kearns-Sayre syndrome with muscle mitochondrial DNA deletion
21. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: A distinctive clinical syndrome
22. LeG(UUR) gene associated with MELAS subgroup of mitochondrial encephalomyopathies
23. Lys mutation
24. Mitochondrial disorders: Clinical and genetic features
25. Mitochondrial disorders
26. Mitochondrial DNA and disease
27. Preclinical detection of Parkinson's disease: Biochemical approaches
28. Leber's hereditary optic neuropathy: A model for mitochondrial neurodegenerative diseases
29. Leber hereditary optic neuropathy: A model system for mitochondrial dysfunction and neurodegeneration
30. Uber hereditare und congenital-angelegte sehnervenleiden
31. Leber's disease and dystonia: A mitochondrial disease
32. Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation
33. A new manifestation of Leber's disease and a new explanation for the agency responsible for its unusual pattern of inheritance
34. A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy
35. A mitochondrial DNA mutation as a cause of Leber's hereditary optic neuropathy
36. MtDNA mutations in Leber's hereditary optic neuropathy
37. Enzyme histochemical studies of senile plaques
38. Nucleoside phosphatase activities associated with the tangles and plaques of Alzheimer's disease: A histochemical study of natural and experimental neurofibrillary tangles
39. Neurofibrillary pathology
40. Positron emission tomography in the study of aging and senile dementia
41. A clinical and physiological study with oxygen-15 and positron tomography
42. Alzheimer's disease: Focal cortical changes shown by positron emission tomography
43. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose
44. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?
45. Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease
46. Mitochondrial function in brain tissue in primary degenerative dementia
47. Cytochrome oxidase deficiency in Alzheimer's disease
48. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease
49. Brain cytochrome oxidase in Alzheimer's disease
50. Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease
51. Electron transport chain defects in Alzheimer's disease brain
52. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease
53. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease
54. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases
55. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
56. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
57. Metabolism of the neurotoxic tertiary amine, MPTP by brain monoamine oxidase
58. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
59. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+ linked substrates by MPP+
60. Energy-dependent uptake of N-methyl-4-phenyl-pyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria
61. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
62. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
63. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
64. Electron transport chain abnormalities in idiopathic Parkinson's disease
65. Mitochondrial complex I deficiency in Parkinson's disease
66. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
67. Mitochondrial function in Parkinson's disease
68. Anatomic and disease specificity of NADH CoQ1 reductase (Complex I) deficiency in Parkinson's disease
69. Disturbances of the respiratory chain in brain from patients with Parkinson's disease
70. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease
71. Decreased NADH ubiquinone oxidoreductase in frontal cortex in Parkinson's disease
72. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease
73. Mitochondrial oxidative phosphorylation defects in Parkinson's disease
74. Is Parkinson's disease a mitochondrial disorder?
75. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy
76. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease
77. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle
78. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease
79. Platelet mitochondrial function in Parkinson's disease: The Royal Kings and Queens Parkinson Disease Research Group
80. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes
81. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease
82. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease
83. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
84. Role of mitochondria in amyotrophic lateral sclerosis
85. Mitochondria in sporadic amyotrophic lateral sclerosis
86. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis
87. Mitochondrial DNA deletion mutation levels are elevated in ALS brains
88. Muscle mitochondrial ATP production in progressive supranuclear palsy
89. Evidence for oxidative stress in subthalamic nucleus in progressive supranuclear palsy
90. Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairment
91. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
92. Regional mitochondrial respiratory activity in Huntington's disease brain
93. Evidence for a defect in NADH:ubiquinone oxidoreductase (complex I) in Huntington's disease
94. Mitochondrial function and parental sex effect in Huntington's disease
95. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy
96. Mitochondrial defect in Huntington's disease caudate nucleus
97. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
98. Complex I defect in muscle from patients with Huntington's disease
99. Friedrech's ataxia: Autosomal recessive disease caused by an intronic FAA triplet repeat expansion
100. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
101. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia
102. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene
103. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene
104. Localization of the Wilson's disease protein product to mitochondria
105. Spastic paraplegia and OX-PHOS impairment caused by mutations in paralegin, a nuclear-encoded mitochondrial metalloprotease
106. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Lever hereditary optic neuropathy and dystonia
107. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency, and blindness
108. A novel deafness/dystonia peptide gene mutation that causes dystonia in female carriers of Mohr-Tranebjaerg syndrome
109. The role of mitochondria in the pathogenesis of neurodegenerative disorders
110. Mitochondrial disorders
111. Mitochondrial respiratory chain disorders, II: Neurodegenerative disorders and nuclear gene defects
112. Disorders related to mitochondrial membranes: Pathology of the respiratory chain and neurodegeneration
113. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative
114. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle
115. Basic FGF attenuates amyloid beta-peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in hippocampal neurons
116. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells
117. Mitochondrial abnormalities in neuroectodermal cells stably expressing human amyloid precursor protein (hAPP751)
118. Beta-amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria
119. The petite mutation in yeast: Loss of mitochondrial deoxyribonucleic acid during induction of petites with ethidium bromide
120. Mitochondrial DNA deficient petite mutants of yeast
121. An established avian fibroblast cell line without mitochondrial DNA
122. Action de l'acriflavine sur les levures, I: La mutation "petite clonie."
123. Intramitochondrial fibers and DNA characteristics, II: Enzymatic and other hydrolytic treatments
124. Tryptose phosphate broth confers to chick embryo cells resistance to the inhibitory effect of chloramphenicol on growth
125. Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation
126. Formation of hybrid cells and heterokaryons by fusion of enucleated and nucleated cells
127. Cytoplasmic inheritance of chloramphenicol resistance in mouse tissue culture cells
128. Lys mutation causing myoclonic epilepsy and ragged red fibers
129. LeG(UUR) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes
130. Lys gene: Two genotypes produce similar phenotypes
131. The mitochondrial genome encodes the complex I defect in Parkinson's disease
132. Origin and functional consequences of the complex I defect in Parkinson's disease
133. Cybrids in Alzheimer's disease: A cellular model of the disease?
134. Use of cytoplasmic hybrid lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease
135. Altered calcium homeostasis and reactive oxygen species production in cells transformed by Alzheimer's disease mitochondrial DNA
136. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids
137. Alzheimer's disease cybrids replicate β-amyloid abnormalities through cell death pathways
138. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
139. Reduced complex I activity in parkinsonian cybrids
140. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
141. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease
142. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease
143. Oxidative stress reduces the mitochondrial membrane potentials in Parkinson's and Alzheimer's disease cybrids
144. L proteins in SH-SY5Y neuroblastoma and in Parkinson's disease cybrid cell lines
145. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappa B in cellular models of Parkinson's disease
146. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid lines
147. As in Parkinson's disease, a bioenergetic defect transfers with mitochondrial DNA of patients with multisystem atrophy
148. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with PSP
149. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients
150. The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy
151. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease
152. Cloning of neuronal mtDNA variants in cultured cells by synaptosome fusion with mtDNA-less cells
153. Histochemical detection of apoptosis in Parkinson's disease
154. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
155. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
156. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
157. Immunohistochemical evidence for apoptosis in Alzheimer's disease
158. A potential role for apoptosis in neurodegeneration and Alzheimer's disease
159. Apoptosis and necrosis: Two distinct events induced, respectively, by mild and intense insults with N-methyl D-aspartate or nitric oxide/superoxide in cortical cell cultures
160. Mitochondrial implication in accidental and programmed cell death: Apoptosis and necrosis
161. From calcium signaling to cell death: Two conformations for the mitochondrial permeability transition pore: Switching from low- to high- conductance state
162. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
163. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
164. Leber's hereditary optic neuropathy: Genetic, biochemical, and phosphorus magnetic resonance spectroscopy study in an Italian family
165. Abnormal lactate after effort in healthy carriers of Leber's hereditary optic neuropathy
166. Screening for mitochondrial cytopathies: The sub-anaerobic threshold exercise test (SATET)
167. Mitochondrial disease: Pulmonary function, exercise performance and blood lactate levels
168. Oral glucose lactate stimulation test in mitochondrial diseases
169. Ultrastructure of skeletal muscle in patients with Parkinson's disease and upper motor lesions
170. The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis
171. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA)
172. Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: Developing the first mouse model of mitochondrial DNA disease